Together, our analysis not only prioritized some new promising drug targets for future drug exploration, but also suggested some known drug targets (NFKB1, SH2B3) that could be exploited for future drug repurposing on autoimmune diseases. This evidence concerns the gene NFKB1 and autoimmune disease.